ISR interim report H1 2022: Full charges ahead of the curve - Redeye
Redeye comments on ISR’s interim half-year 2022 report. It has been an eventful first-half year and intense work for ISR in terms of the clinical development of the company’s HIV drug candidate ISR48 and their nasally inhaled dry powder vaccine against SARS-CoV-2 ISR52, laying the fundaments for commercialization. However, Redeye notes that ISR is in a precarious financial situation, and the next coming months will be decisive for ISR’s future direction.
Länk till analysen i sin helhet: https://www.redeye.se/research/854780/isr-interim-report-h1-2022-full-charges-ahead-of-the-curve?utm_source=finwire&utm_medium=RSS